Mehdi Shahidi

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto et al. · Journal of Clinical Oncology · 2013 · 3.2K citations

Medicine, Oncology, Pharmacology +17

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler et al. · The Lancet Oncology · 2015 · 1.6K citations

Medicine, Oncology, Pharmacology +13

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne et al. · The Lancet Oncology · 2016 · 1.2K citations

Medicine, Oncology, Pharmacology +11

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel et al. · The Lancet Oncology · 2012 · 953 citations

Medicine, Oncology, Pharmacology +10

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su et al. · The Lancet Oncology · 2012 · 405 citations

Medicine, Oncology, Pharmacotherapy +13